Syntopix Group plc is a drug discovery and development company engaged in the discovery and development of drugs for the topical treatment of dermatological diseases. The Company is focused on acne and staphylococcus aureus infections.
12/11/09
Syntopix (AIM: SYN) took another step closer to commercialising a new product targeting a large consumer healthcare market, reporting good results from the trials of its new antimicrobial compound for the treatment of the acne.
23/08/10
Syntopix signs collaboration deal with 'healthcare world leader'15/03/10
Syntopix set to raise £2 mln in placing to fund business development12/03/10
Syntopix making progress towards antimicrobial commercialisation; plans fundraising07/01/10
Syntopix says FY revenues up 34.8% as losses narrow, plans equity issue to explore market opportunit14/04/09
Syntopix signs exclusive evaluation agreement with “major” consumer healthcare company
Copyright © Proactiveinvestors.co.uk, 2012. All Rights Reserved Design & Development: Tehnicom Computers
